Wall Street analysts expect that Fate Therapeutics, Inc. (NASDAQ:FATE) will report $1.01 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Fate Therapeutics’ earnings, with the lowest sales estimate coming in at $1.00 million and the highest estimate coming in at $1.03 million. Fate Therapeutics reported sales of $1.03 million during the same quarter last year, which indicates a negative year-over-year growth rate of 1.9%. The business is scheduled to issue its next quarterly earnings report on Monday, November 6th.

On average, analysts expect that Fate Therapeutics will report full year sales of $1.01 million for the current fiscal year, with estimates ranging from $3.00 million to $4.11 million. For the next financial year, analysts forecast that the company will post sales of $6.06 million per share, with estimates ranging from $4.02 million to $12.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Fate Therapeutics.

Fate Therapeutics (NASDAQ:FATE) last issued its quarterly earnings data on Monday, August 14th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.24) by $0.01. Fate Therapeutics had a negative net margin of 887.68% and a negative return on equity of 67.01%. The business had revenue of $1.03 million during the quarter, compared to the consensus estimate of $1.02 million.

Several research analysts have recently weighed in on the stock. Leerink Swann reissued an “outperform” rating and set a $7.00 price objective on shares of Fate Therapeutics in a report on Friday, September 8th. Zacks Investment Research raised shares of Fate Therapeutics from a “hold” rating to a “buy” rating and set a $4.75 price objective for the company in a report on Friday, September 8th. HC Wainwright reissued a “buy” rating and set a $7.00 price objective on shares of Fate Therapeutics in a report on Thursday. Finally, ValuEngine cut shares of Fate Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, September 22nd. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $6.79.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. EcoR1 Capital LLC purchased a new position in shares of Fate Therapeutics during the first quarter valued at approximately $11,543,000. Wells Fargo & Company MN raised its holdings in shares of Fate Therapeutics by 926.7% during the first quarter. Wells Fargo & Company MN now owns 281,111 shares of the biopharmaceutical company’s stock valued at $1,279,000 after purchasing an additional 253,732 shares during the last quarter. Morgan Stanley raised its holdings in shares of Fate Therapeutics by 9.8% during the first quarter. Morgan Stanley now owns 611,646 shares of the biopharmaceutical company’s stock valued at $2,783,000 after purchasing an additional 54,615 shares during the last quarter. Driehaus Capital Management LLC purchased a new position in shares of Fate Therapeutics during the first quarter valued at approximately $145,000. Finally, Neuberger Berman Group LLC purchased a new position in shares of Fate Therapeutics during the first quarter valued at approximately $312,000. 64.27% of the stock is owned by hedge funds and other institutional investors.

Fate Therapeutics (FATE) traded up 4.501% on Thursday, hitting $4.295. 120,901 shares of the stock were exchanged. Fate Therapeutics has a 12 month low of $1.80 and a 12 month high of $5.68. The company has a 50-day moving average of $3.97 and a 200-day moving average of $3.68. The stock’s market cap is $177.88 million.

TRADEMARK VIOLATION WARNING: This article was originally published by American Banking News and is the property of of American Banking News. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://www.americanbankingnews.com/2017/10/12/1-01-million-in-sales-expected-for-fate-therapeutics-inc-fate-this-quarter.html.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

Get a free copy of the Zacks research report on Fate Therapeutics (FATE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Fate Therapeutics (NASDAQ:FATE)

Receive News & Ratings for Fate Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.